Form 4: UTHR CEO Exercises, Sells Stock Options Under 10b5-1 Plan

United Therapeutics Corp's Chairperson and CEO, Martine A. Rothblatt, exercised and sold common stock options totaling 8,000 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO, Director, and 10% Owner of United Therapeutics Corp (UTHR), reported transactions involving the exercise and sale of common stock options.
• On October 13, 2025, Rothblatt acquired 4,000 shares of common stock by exercising options at a price of $120.26 per share.
• On the same day, she disposed of 1,000 shares at $437.53 per share and 3,000 shares at a weighted average price of $441.4 per share.
• On October 14, 2025, Rothblatt acquired another 4,000 shares of common stock by exercising options at $120.26 per share.
• Also on October 14, 2025, she disposed of 522 shares at $432.74 per share, 1,478 shares at a weighted average price of $434.0077 per share, and 2,000 shares at $441.26 per share.
• All reported exercises and sales were executed pursuant to a pre-arranged 10b5-1 trading plan, which was entered into on May 2, 2025.
• The 10b5-1 plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly owns 130 shares of common stock and indirectly owns 166 shares by spouse, 324,518 shares by one trust, 258,117 shares by another trust, 45,596 shares by a third trust, and 15,962 shares by a fourth trust.
• Remaining stock options beneficially owned after these transactions are 186,000, with an exercise price of $120.26 and an expiration date of March 15, 2026.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (exercise and sale of stock options) under a pre-arranged 10b5-1 trading plan. This type of transaction is generally neutral, as it reflects personal financial planning rather than a change in the company's fundamental outlook or performance.

Positives

• The exercise price of $120.26 per share is significantly lower than the sale prices, indicating a profitable transaction for the reporting person.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than a reaction to immediate company performance.

Future Outlook

The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for sales executed in multiple trades.

Industry Context

This filing reports routine insider transactions for a publicly traded biotechnology and pharmaceutical company. Such transactions, especially when conducted under a 10b5-1 plan, are generally considered part of an executive's personal financial management and typically do not reflect new information about the company's operational performance or strategic position within the industry.

Related Party Transactions

• Shares are held indirectly by spouse.
• Shares are held indirectly in family trusts where the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• Shares are held indirectly in family trusts where the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
• Shares are held indirectly in family trusts where the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
• Shares are held indirectly in family trusts where the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, pre-arranged insider transactions and do not signal new information about company performance or strategy.

Next Steps

• Continuation of the pre-arranged 10b5-1 trading plan until its specified termination conditions are met.

Key Dates

Recommendation

This Form 4 details routine insider transactions (exercise and sale of stock options) by the CEO under a pre-arranged 10b5-1 trading plan. Such transactions are typically not indicative of management's view on future company performance and are often for personal financial planning or diversification. The filing does not contain new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new fundamental data to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Biotechnology, Pharmaceuticals